Document Detail


Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
MedLine Citation:
PMID:  23137412     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Most patients with type 2 diabetes mellitus (T2DM) are prescribed multiple medications - typically more than one for glycemic control alone, and others for the management of lipids and hypertension. Within a few years following diagnosis, many patients progress beyond an initial starting regimen of metformin and/or sulfonylurea in order to maintain glycemic control. With the broad selection of antidiabetes medications available today, the choice of which agents to add when progressing from monotherapy to combination therapy has led to much discussion on how to best tailor a treatment regimen to the individual patient's needs.
AREAS COVERED: The aim of this paper is to review the literature describing the use of linagliptin as a component of combination therapy for the treatment of T2DM. Literature searches were conducted to retrieve articles reporting on linagliptin clinical trial data. For comparison of safety and efficacy, studies of linagliptin as monotherapy were included.
EXPERT OPINION: Dipeptidyl peptidase-4 inhibitors are used across all stages of treatment, from monotherapy to dual or triple therapy regimens for glycemic control. Linagliptin has been studied in combination with the most commonly used classes of antihyperglycemic medications, with demonstrated efficacy and a safety profile comparable to placebo.
Authors:
Rosemarie Lajara
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-09
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-26     Completed Date:  2013-04-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2663-71     Citation Subset:  IM    
Affiliation:
Diabetes America, Health Center at Plano, 1708 Coit Road, Suite 100, Plano, TX 75075, USA. rlajara@diabetesamerica.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / adverse effects,  therapeutic use*
Drug Therapy, Combination / adverse effects
Evidence-Based Medicine
Humans
Hypoglycemic Agents / adverse effects,  therapeutic use
Purines / adverse effects,  therapeutic use*
Quinazolines / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Purines; 0/Quinazolines; 3X29ZEJ4R2/Linagliptin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Geriatric gynecology.
Next Document:  Genetic Testing in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Interventi...